OncoRx Pharmaceuticals

OncoRx Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing targeted therapies for central nervous system (CNS) cancers, including glioblastoma multiforme and brain metastases. The company's approach leverages proprietary nanoparticle formulations to improve the delivery of potent anti-cancer agents across the blood-brain barrier. Its lead candidate, ORX-301, is a nanoparticle-based microtubule inhibitor designed to enhance efficacy while minimizing systemic toxicity in patients with aggressive brain tumors. Headquartered in San Diego, OncoRx aims to address the significant unmet medical need in neuro-oncology through innovative drug delivery technologies.